Ann Scherzinger
Concepts (302)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Adipose Tissue | 15 | 2020 | 662 | 1.110 |
Why?
| Fatty Liver | 6 | 2021 | 271 | 0.950 |
Why?
| Insulin Resistance | 13 | 2022 | 1140 | 0.910 |
Why?
| Adiposity | 10 | 2021 | 482 | 0.890 |
Why?
| Tomography, X-Ray Computed | 16 | 2019 | 2370 | 0.880 |
Why?
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2019 | 117 | 0.750 |
Why?
| Radiation Dosage | 1 | 2019 | 144 | 0.750 |
Why?
| Obesity | 14 | 2019 | 2602 | 0.670 |
Why?
| Abdominal Fat | 6 | 2022 | 44 | 0.670 |
Why?
| Data Display | 2 | 2016 | 23 | 0.660 |
Why?
| Machine Learning | 1 | 2019 | 239 | 0.650 |
Why?
| Diagnostic Imaging | 2 | 2016 | 268 | 0.650 |
Why?
| Radiographic Image Enhancement | 1 | 2016 | 68 | 0.630 |
Why?
| Signal Processing, Computer-Assisted | 1 | 2016 | 138 | 0.610 |
Why?
| Magnetic Resonance Spectroscopy | 3 | 2013 | 527 | 0.570 |
Why?
| Intra-Abdominal Fat | 5 | 2022 | 88 | 0.540 |
Why?
| Muscle, Skeletal | 6 | 2021 | 1406 | 0.490 |
Why?
| Non-alcoholic Fatty Liver Disease | 5 | 2020 | 239 | 0.490 |
Why?
| HIV Infections | 7 | 2021 | 2458 | 0.480 |
Why?
| Diabetes, Gestational | 4 | 2019 | 263 | 0.460 |
Why?
| Anti-HIV Agents | 4 | 2021 | 674 | 0.460 |
Why?
| User-Computer Interface | 2 | 2016 | 162 | 0.440 |
Why?
| Overnutrition | 2 | 2019 | 41 | 0.370 |
Why?
| Polycystic Ovary Syndrome | 2 | 2022 | 161 | 0.360 |
Why?
| Body Mass Index | 13 | 2019 | 2076 | 0.360 |
Why?
| Magnetic Resonance Imaging | 17 | 2021 | 3017 | 0.360 |
Why?
| Subcutaneous Fat | 5 | 2021 | 84 | 0.340 |
Why?
| Diabetes Mellitus, Type 2 | 4 | 2018 | 2001 | 0.330 |
Why?
| Lung Neoplasms | 1 | 2019 | 2158 | 0.330 |
Why?
| Imaging, Three-Dimensional | 2 | 2013 | 548 | 0.330 |
Why?
| Anatomy | 2 | 2006 | 27 | 0.320 |
Why?
| Pediatric Obesity | 2 | 2022 | 390 | 0.310 |
Why?
| Computer-Assisted Instruction | 2 | 2006 | 71 | 0.310 |
Why?
| Cardiovascular Diseases | 3 | 2013 | 1695 | 0.300 |
Why?
| Prenatal Exposure Delayed Effects | 3 | 2019 | 458 | 0.270 |
Why?
| Education, Medical, Undergraduate | 1 | 2006 | 170 | 0.260 |
Why?
| Liver | 4 | 2021 | 1859 | 0.260 |
Why?
| Diet | 2 | 2021 | 1070 | 0.260 |
Why?
| Humans | 63 | 2022 | 112249 | 0.260 |
Why?
| Growth Hormone-Releasing Hormone | 2 | 2021 | 30 | 0.250 |
Why?
| Phantoms, Imaging | 2 | 2014 | 137 | 0.250 |
Why?
| Female | 50 | 2022 | 62624 | 0.250 |
Why?
| Biomarkers | 6 | 2021 | 3464 | 0.240 |
Why?
| Body Composition | 8 | 2021 | 738 | 0.240 |
Why?
| Lipid Metabolism | 2 | 2019 | 533 | 0.240 |
Why?
| Ultrasonography | 5 | 2013 | 764 | 0.230 |
Why?
| Male | 42 | 2021 | 60715 | 0.220 |
Why?
| Raltegravir Potassium | 1 | 2020 | 18 | 0.220 |
Why?
| Darunavir | 1 | 2020 | 17 | 0.220 |
Why?
| Atazanavir Sulfate | 1 | 2020 | 49 | 0.210 |
Why?
| Adolescent | 19 | 2022 | 18577 | 0.210 |
Why?
| Metabolic Diseases | 1 | 2021 | 112 | 0.210 |
Why?
| Neoplasms | 1 | 2013 | 2009 | 0.200 |
Why?
| Muscles | 1 | 2020 | 326 | 0.200 |
Why?
| Postpartum Period | 1 | 2001 | 240 | 0.190 |
Why?
| Bone Density | 2 | 2014 | 399 | 0.190 |
Why?
| Obesity, Abdominal | 1 | 2018 | 34 | 0.190 |
Why?
| Lipolysis | 1 | 2018 | 49 | 0.190 |
Why?
| African Americans | 6 | 2011 | 1096 | 0.180 |
Why?
| Risk Factors | 10 | 2021 | 8978 | 0.160 |
Why?
| Lipase | 2 | 2021 | 84 | 0.160 |
Why?
| Weight Loss | 2 | 2014 | 692 | 0.160 |
Why?
| Reference Standards | 1 | 2016 | 195 | 0.160 |
Why?
| Body Constitution | 4 | 2012 | 66 | 0.150 |
Why?
| Prospective Studies | 7 | 2021 | 6167 | 0.150 |
Why?
| Anti-Retroviral Agents | 1 | 2017 | 196 | 0.150 |
Why?
| Absorptiometry, Photon | 5 | 2018 | 242 | 0.150 |
Why?
| Linear Models | 4 | 2021 | 909 | 0.150 |
Why?
| Adiponectin | 2 | 2013 | 208 | 0.150 |
Why?
| Body Fat Distribution | 2 | 2013 | 46 | 0.140 |
Why?
| Middle Aged | 20 | 2020 | 28676 | 0.140 |
Why?
| Adult | 26 | 2021 | 31789 | 0.140 |
Why?
| Child | 12 | 2021 | 17357 | 0.140 |
Why?
| Catecholamines | 1 | 1994 | 117 | 0.140 |
Why?
| Habituation, Psychophysiologic | 1 | 1994 | 39 | 0.140 |
Why?
| Guidelines as Topic | 1 | 2016 | 285 | 0.140 |
Why?
| Hippocampus | 2 | 2002 | 793 | 0.130 |
Why?
| Schizophrenic Psychology | 1 | 1994 | 136 | 0.130 |
Why?
| Anthropometry | 4 | 2017 | 197 | 0.130 |
Why?
| Portal Vein | 1 | 2014 | 95 | 0.130 |
Why?
| Arousal | 1 | 1994 | 208 | 0.130 |
Why?
| Schizophrenia | 2 | 2002 | 588 | 0.130 |
Why?
| Abdomen | 2 | 2003 | 123 | 0.130 |
Why?
| Elasticity Imaging Techniques | 1 | 2013 | 32 | 0.130 |
Why?
| Health | 1 | 2013 | 77 | 0.130 |
Why?
| Cohort Studies | 10 | 2013 | 4937 | 0.130 |
Why?
| Adolescent Development | 1 | 2013 | 97 | 0.130 |
Why?
| Longitudinal Studies | 5 | 2021 | 2673 | 0.120 |
Why?
| Hyperinsulinism | 1 | 2013 | 111 | 0.120 |
Why?
| Industry | 1 | 2013 | 86 | 0.120 |
Why?
| Evoked Potentials, Auditory | 1 | 1994 | 262 | 0.120 |
Why?
| Postmenopause | 1 | 2014 | 332 | 0.120 |
Why?
| Muscle Cells | 1 | 2012 | 44 | 0.120 |
Why?
| Bone and Bones | 1 | 2014 | 251 | 0.120 |
Why?
| Skinfold Thickness | 3 | 2012 | 54 | 0.120 |
Why?
| Vacuum Curettage | 1 | 2011 | 4 | 0.120 |
Why?
| Lipectomy | 1 | 2011 | 14 | 0.110 |
Why?
| HIV Protease Inhibitors | 2 | 2021 | 76 | 0.110 |
Why?
| Image Processing, Computer-Assisted | 5 | 2002 | 725 | 0.110 |
Why?
| Exercise | 2 | 2019 | 1687 | 0.110 |
Why?
| Down-Regulation | 1 | 2013 | 681 | 0.110 |
Why?
| Aging | 2 | 2013 | 1711 | 0.110 |
Why?
| Bariatric Surgery | 1 | 2013 | 159 | 0.110 |
Why?
| Genetic Predisposition to Disease | 4 | 2021 | 2406 | 0.110 |
Why?
| Inflammation | 1 | 2021 | 2427 | 0.110 |
Why?
| Attention | 1 | 1994 | 467 | 0.110 |
Why?
| Overweight | 2 | 2013 | 464 | 0.100 |
Why?
| Membrane Proteins | 2 | 2021 | 1091 | 0.100 |
Why?
| Exercise Therapy | 1 | 2014 | 362 | 0.100 |
Why?
| Breast Diseases | 1 | 1989 | 18 | 0.100 |
Why?
| Cross-Sectional Studies | 6 | 2021 | 4207 | 0.100 |
Why?
| Follow-Up Studies | 5 | 2021 | 4887 | 0.100 |
Why?
| Multiple Sclerosis | 3 | 1998 | 322 | 0.100 |
Why?
| Breast Feeding | 1 | 2012 | 347 | 0.100 |
Why?
| Predictive Value of Tests | 2 | 2013 | 2021 | 0.090 |
Why?
| Pharynx | 1 | 2008 | 55 | 0.090 |
Why?
| Fetal Growth Retardation | 1 | 2013 | 431 | 0.090 |
Why?
| Child Development | 1 | 2013 | 469 | 0.090 |
Why?
| National Library of Medicine (U.S.) | 2 | 2006 | 12 | 0.090 |
Why?
| Regression Analysis | 4 | 2012 | 1136 | 0.090 |
Why?
| Subcutaneous Fat, Abdominal | 2 | 2022 | 17 | 0.090 |
Why?
| Prevalence | 4 | 2019 | 2383 | 0.090 |
Why?
| Insulin | 3 | 2022 | 2167 | 0.080 |
Why?
| Risk | 4 | 2013 | 944 | 0.080 |
Why?
| Visible Human Projects | 1 | 2006 | 4 | 0.080 |
Why?
| Waist Circumference | 2 | 2019 | 131 | 0.080 |
Why?
| Chromosomes, Human, Pair 17 | 1 | 2006 | 75 | 0.080 |
Why?
| Lung | 1 | 2019 | 3586 | 0.080 |
Why?
| Breast Neoplasms | 4 | 1995 | 1889 | 0.080 |
Why?
| Obesity, Morbid | 1 | 2008 | 178 | 0.080 |
Why?
| Oxygen Consumption | 1 | 2008 | 663 | 0.080 |
Why?
| Fractures, Bone | 1 | 2010 | 334 | 0.080 |
Why?
| Disease Progression | 1 | 2013 | 2474 | 0.080 |
Why?
| Prognosis | 3 | 2021 | 3532 | 0.080 |
Why?
| Radiography | 2 | 2013 | 828 | 0.070 |
Why?
| Models, Anatomic | 2 | 1996 | 102 | 0.070 |
Why?
| Reproducibility of Results | 3 | 2013 | 2877 | 0.070 |
Why?
| Models, Structural | 1 | 1983 | 43 | 0.070 |
Why?
| Arteriosclerosis | 1 | 2004 | 111 | 0.070 |
Why?
| Pregnancy | 4 | 2019 | 5185 | 0.070 |
Why?
| Quantitative Trait, Heritable | 1 | 2005 | 141 | 0.070 |
Why?
| Ultrasonics | 1 | 1983 | 65 | 0.060 |
Why?
| Self Report | 2 | 2021 | 677 | 0.060 |
Why?
| Aged | 10 | 2014 | 20025 | 0.060 |
Why?
| United States | 5 | 2021 | 12170 | 0.060 |
Why?
| Diabetes Mellitus, Type 1 | 1 | 2018 | 3262 | 0.060 |
Why?
| Starch | 1 | 2022 | 24 | 0.060 |
Why?
| Sleep | 1 | 2008 | 695 | 0.060 |
Why?
| Lipodystrophy | 1 | 2001 | 17 | 0.060 |
Why?
| Young Adult | 6 | 2019 | 10899 | 0.060 |
Why?
| Viral Load | 2 | 2020 | 470 | 0.060 |
Why?
| Brain | 5 | 1998 | 2664 | 0.060 |
Why?
| Diet Surveys | 1 | 2021 | 82 | 0.060 |
Why?
| Lipopolysaccharide Receptors | 1 | 2021 | 99 | 0.060 |
Why?
| Body Size | 2 | 2012 | 97 | 0.060 |
Why?
| Italy | 1 | 2020 | 89 | 0.050 |
Why?
| Colorado | 3 | 2019 | 4552 | 0.050 |
Why?
| Fasting | 1 | 2022 | 278 | 0.050 |
Why?
| Family | 1 | 2004 | 569 | 0.050 |
Why?
| Hospitals, Teaching | 1 | 2020 | 112 | 0.050 |
Why?
| Phenotype | 4 | 2013 | 3010 | 0.050 |
Why?
| Diabetes Mellitus | 2 | 2009 | 960 | 0.050 |
Why?
| Immune System | 1 | 2021 | 198 | 0.050 |
Why?
| Genetic Markers | 1 | 2021 | 402 | 0.050 |
Why?
| Vegetables | 1 | 2020 | 119 | 0.050 |
Why?
| HIV | 1 | 2021 | 204 | 0.050 |
Why?
| Antiretroviral Therapy, Highly Active | 1 | 2021 | 282 | 0.050 |
Why?
| Aged, 80 and over | 5 | 2013 | 6778 | 0.050 |
Why?
| C-Reactive Protein | 1 | 2021 | 362 | 0.050 |
Why?
| Gene-Environment Interaction | 1 | 2021 | 234 | 0.050 |
Why?
| Eating | 1 | 2022 | 361 | 0.050 |
Why?
| Triglycerides | 1 | 2022 | 542 | 0.050 |
Why?
| Retrospective Studies | 4 | 2020 | 11118 | 0.050 |
Why?
| Child Behavior | 1 | 2021 | 259 | 0.050 |
Why?
| Glucose Tolerance Test | 3 | 2009 | 393 | 0.050 |
Why?
| Glucose Clamp Technique | 1 | 2018 | 206 | 0.050 |
Why?
| HIV-1 | 2 | 2020 | 793 | 0.040 |
Why?
| Fatty Acids, Nonesterified | 1 | 2018 | 177 | 0.040 |
Why?
| Treatment Outcome | 3 | 2021 | 8944 | 0.040 |
Why?
| Canada | 1 | 2019 | 330 | 0.040 |
Why?
| Interleukin-6 | 1 | 2021 | 705 | 0.040 |
Why?
| Blood Glucose | 3 | 2018 | 1908 | 0.040 |
Why?
| Radiography, Abdominal | 1 | 2017 | 35 | 0.040 |
Why?
| Interferon-beta | 1 | 1998 | 90 | 0.040 |
Why?
| Weight Gain | 1 | 2001 | 487 | 0.040 |
Why?
| Drug Therapy, Combination | 1 | 2020 | 999 | 0.040 |
Why?
| Estrogen Replacement Therapy | 1 | 1997 | 131 | 0.040 |
Why?
| Multivariate Analysis | 2 | 2012 | 1599 | 0.040 |
Why?
| Adolescent Behavior | 1 | 2021 | 514 | 0.040 |
Why?
| Pilot Projects | 3 | 2014 | 1406 | 0.040 |
Why?
| Aspartic Acid | 1 | 1995 | 89 | 0.040 |
Why?
| Gated Blood-Pool Imaging | 1 | 1995 | 10 | 0.040 |
Why?
| Pedigree | 2 | 2009 | 518 | 0.040 |
Why?
| Health Behavior | 1 | 2021 | 716 | 0.040 |
Why?
| Energy Metabolism | 1 | 2001 | 901 | 0.040 |
Why?
| Polycystic Kidney, Autosomal Dominant | 1 | 1997 | 186 | 0.040 |
Why?
| Vanilmandelic Acid | 1 | 1994 | 5 | 0.040 |
Why?
| Homovanillic Acid | 1 | 1994 | 12 | 0.040 |
Why?
| Methoxyhydroxyphenylglycol | 1 | 1994 | 14 | 0.040 |
Why?
| Cerebrospinal Fluid | 1 | 1994 | 95 | 0.030 |
Why?
| Bone Marrow Transplantation | 1 | 1995 | 291 | 0.030 |
Why?
| Femur Neck | 1 | 2014 | 52 | 0.030 |
Why?
| Mothers | 1 | 2019 | 587 | 0.030 |
Why?
| Glycated Hemoglobin A | 1 | 2018 | 822 | 0.030 |
Why?
| Cysts | 2 | 1997 | 84 | 0.030 |
Why?
| Macaca fascicularis | 1 | 2013 | 52 | 0.030 |
Why?
| Recurrence | 2 | 2011 | 954 | 0.030 |
Why?
| Weight Reduction Programs | 1 | 2014 | 103 | 0.030 |
Why?
| Neural Inhibition | 1 | 1994 | 175 | 0.030 |
Why?
| Amygdala | 1 | 1994 | 184 | 0.030 |
Why?
| Acoustic Stimulation | 1 | 1994 | 367 | 0.030 |
Why?
| Intracellular Space | 1 | 2012 | 81 | 0.030 |
Why?
| Equipment Design | 1 | 2014 | 530 | 0.030 |
Why?
| Liver Diseases | 2 | 1997 | 270 | 0.030 |
Why?
| Leptin | 1 | 2013 | 225 | 0.030 |
Why?
| Thinness | 1 | 2012 | 90 | 0.030 |
Why?
| Child Nutritional Physiological Phenomena | 1 | 2012 | 100 | 0.030 |
Why?
| Psychiatric Status Rating Scales | 1 | 1994 | 565 | 0.030 |
Why?
| Ventricular Function, Left | 1 | 1995 | 484 | 0.030 |
Why?
| Dopamine | 1 | 1994 | 354 | 0.030 |
Why?
| Puberty | 1 | 2012 | 139 | 0.030 |
Why?
| Polymorphism, Single Nucleotide | 2 | 2011 | 2029 | 0.030 |
Why?
| Adenofibroma | 1 | 1989 | 2 | 0.020 |
Why?
| Southwestern United States | 1 | 2009 | 100 | 0.020 |
Why?
| Chi-Square Distribution | 1 | 2010 | 572 | 0.020 |
Why?
| Calorimetry | 1 | 2008 | 67 | 0.020 |
Why?
| Evaluation Studies as Topic | 1 | 1989 | 226 | 0.020 |
Why?
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1989 | 54 | 0.020 |
Why?
| Survival Rate | 1 | 2013 | 1851 | 0.020 |
Why?
| Metabolic Syndrome | 1 | 2012 | 384 | 0.020 |
Why?
| Sleep Apnea Syndromes | 1 | 2008 | 90 | 0.020 |
Why?
| Atherosclerosis | 1 | 2011 | 301 | 0.020 |
Why?
| Minority Groups | 1 | 2009 | 199 | 0.020 |
Why?
| Statistics as Topic | 1 | 1989 | 365 | 0.020 |
Why?
| Chronic Disease | 1 | 1994 | 1666 | 0.020 |
Why?
| Myocardial Infarction | 1 | 1995 | 1111 | 0.020 |
Why?
| Child, Preschool | 1 | 2021 | 9655 | 0.020 |
Why?
| Carbon Dioxide | 1 | 2008 | 246 | 0.020 |
Why?
| Spleen | 1 | 2009 | 558 | 0.020 |
Why?
| Observer Variation | 2 | 1997 | 333 | 0.020 |
Why?
| Urban Health | 1 | 2006 | 87 | 0.020 |
Why?
| Breast | 2 | 1988 | 141 | 0.020 |
Why?
| Rural Health | 1 | 2006 | 96 | 0.020 |
Why?
| Microsatellite Repeats | 1 | 2006 | 170 | 0.020 |
Why?
| Waist-Hip Ratio | 1 | 2005 | 28 | 0.020 |
Why?
| Energy Intake | 1 | 2008 | 493 | 0.020 |
Why?
| Body Weight | 2 | 2000 | 1016 | 0.020 |
Why?
| Chromosome Mapping | 1 | 2006 | 570 | 0.020 |
Why?
| Los Angeles | 1 | 2004 | 59 | 0.020 |
Why?
| Models, Statistical | 1 | 2009 | 688 | 0.020 |
Why?
| Age Factors | 1 | 2012 | 3330 | 0.020 |
Why?
| Texas | 1 | 2004 | 184 | 0.020 |
Why?
| Genetic Linkage | 1 | 2005 | 364 | 0.020 |
Why?
| Scattering, Radiation | 1 | 1983 | 120 | 0.020 |
Why?
| Infant, Newborn | 1 | 2012 | 5017 | 0.010 |
Why?
| CD4 Lymphocyte Count | 1 | 2001 | 300 | 0.010 |
Why?
| Viscera | 1 | 2000 | 19 | 0.010 |
Why?
| Reference Values | 1 | 2002 | 876 | 0.010 |
Why?
| Time Factors | 1 | 2012 | 7054 | 0.010 |
Why?
| Leg | 1 | 2001 | 237 | 0.010 |
Why?
| Homeostasis | 1 | 2003 | 595 | 0.010 |
Why?
| Radioimmunoassay | 1 | 1999 | 180 | 0.010 |
Why?
| Risk Assessment | 1 | 2009 | 3137 | 0.010 |
Why?
| Genotype | 1 | 2005 | 2070 | 0.010 |
Why?
| Interferon beta-1a | 1 | 1998 | 15 | 0.010 |
Why?
| Glucose | 1 | 2003 | 866 | 0.010 |
Why?
| Antipyrine | 1 | 1997 | 7 | 0.010 |
Why?
| Body Height | 1 | 1999 | 187 | 0.010 |
Why?
| Injections, Intramuscular | 1 | 1998 | 127 | 0.010 |
Why?
| RNA, Viral | 1 | 2001 | 589 | 0.010 |
Why?
| Gadolinium | 1 | 1998 | 79 | 0.010 |
Why?
| Mathematical Computing | 1 | 1997 | 18 | 0.010 |
Why?
| Caffeine | 1 | 1997 | 66 | 0.010 |
Why?
| Algorithms | 2 | 1995 | 1548 | 0.010 |
Why?
| Hormones | 1 | 1997 | 136 | 0.010 |
Why?
| Tissue Embedding | 1 | 1996 | 6 | 0.010 |
Why?
| Histological Techniques | 1 | 1996 | 42 | 0.010 |
Why?
| Psychoses, Substance-Induced | 1 | 1995 | 20 | 0.010 |
Why?
| Diagnostic Errors | 1 | 1997 | 158 | 0.010 |
Why?
| Coronary Disease | 1 | 1999 | 469 | 0.010 |
Why?
| Freezing | 1 | 1996 | 123 | 0.010 |
Why?
| Neurologic Examination | 1 | 1995 | 132 | 0.010 |
Why?
| Fluoroscopy | 1 | 1996 | 138 | 0.010 |
Why?
| Ischemic Attack, Transient | 1 | 1995 | 52 | 0.010 |
Why?
| Cadaver | 1 | 1996 | 269 | 0.010 |
Why?
| Decision Making, Computer-Assisted | 1 | 1995 | 22 | 0.010 |
Why?
| Analysis of Variance | 1 | 1999 | 1517 | 0.010 |
Why?
| Biophysical Phenomena | 1 | 1994 | 67 | 0.010 |
Why?
| Information Services | 1 | 1995 | 52 | 0.010 |
Why?
| Radiology Information Systems | 1 | 1995 | 34 | 0.010 |
Why?
| Biophysics | 1 | 1994 | 74 | 0.010 |
Why?
| Double-Blind Method | 1 | 1998 | 1670 | 0.010 |
Why?
| Sex Factors | 1 | 1999 | 1995 | 0.010 |
Why?
| Combined Modality Therapy | 1 | 1995 | 1240 | 0.010 |
Why?
| Neoplasm Staging | 1 | 1995 | 1220 | 0.010 |
Why?
| Stroke Volume | 1 | 1995 | 515 | 0.010 |
Why?
| Sensitivity and Specificity | 1 | 1997 | 1926 | 0.010 |
Why?
| Animals | 1 | 2013 | 35194 | 0.010 |
Why?
| Models, Theoretical | 1 | 1995 | 608 | 0.010 |
Why?
| Dose-Response Relationship, Drug | 1 | 1995 | 2226 | 0.010 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 1995 | 569 | 0.010 |
Why?
| Kidney | 1 | 1997 | 1187 | 0.010 |
Why?
|
|
Scherzinger's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|